Human Serum calibrator 3 (2X)
- Known as:
- Human Serum calibrator 3 (2X)
- Catalog number:
- 35-s63010000-l4
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- Human Serum calibrator 3 (2X)
Related genes to: Human Serum calibrator 3 (2X)
- Gene:
- MAN2A2 NIH gene
- Name:
- mannosidase alpha class 2A member 2
- Previous symbol:
- -
- Synonyms:
- MANA2X, HsT19662
- Chromosome:
- 15q25
- Locus Type:
- gene with protein product
- Date approved:
- 1997-07-01
- Date modifiied:
- 2016-01-22
- Gene:
- MYH1 NIH gene
- Name:
- myosin heavy chain 1
- Previous symbol:
- -
- Synonyms:
- MYHSA1, MYHa, MyHC-2X/D, MGC133384
- Chromosome:
- 17p13.1
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-06-22
- Gene:
- P2RX1 NIH gene
- Name:
- purinergic receptor P2X 1
- Previous symbol:
- -
- Synonyms:
- P2X1
- Chromosome:
- 17p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1997-01-16
- Date modifiied:
- 2016-02-05
- Gene:
- P2RX2 NIH gene
- Name:
- purinergic receptor P2X 2
- Previous symbol:
- DFNA41
- Synonyms:
- P2X2
- Chromosome:
- 12q24.33
- Locus Type:
- gene with protein product
- Date approved:
- 2001-03-30
- Date modifiied:
- 2016-02-05
- Gene:
- P2RX3 NIH gene
- Name:
- purinergic receptor P2X 3
- Previous symbol:
- -
- Synonyms:
- P2X3
- Chromosome:
- 11q12.1
- Locus Type:
- gene with protein product
- Date approved:
- 1997-10-09
- Date modifiied:
- 2016-10-05
Related products to: Human Serum calibrator 3 (2X)
Related articles to: Human Serum calibrator 3 (2X)
- In this phase II study, 47 patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) received three cycles of pembrolizumab plus chemotherapy, followed by Da Vinci robot-assisted surgery. The primary endpoints were safety and major pathological response (MPR). Key secondary endpoints included complete pathological response (pCR) and survival. No grade ≥3 adverse events or surgical delays occurred during neoadjuvant therapy. Among 46 patients studied for efficacy, the MPR and pCR rates were 72% and 41%, respectively. After a median follow-up of 27.2 months, the 2-year overall survival (OS) and disease-free survival (DFS) rates were 91% and 89%, respectively. Expansion of TRGC2 NKT cells in peripheral blood correlated with neoadjuvant treatment effectiveness, which was validated by in vitro organoid experiments and external cancer datasets, and its functional classification and mechanism of action were further explored. These findings show preoperative pembrolizumab plus chemotherapy is a promising therapeutic strategy for resectable ESCC. - Source: PubMed
Shang XiaobinXie YongjieYu JinpuZhang ChenZhao GangLiang FeiLiu LiangZhang WeihongLi RunmeiYu WenwenYue JieChen ChuanguiDuan XiaofengMa ZhaoChen ZuoyuXiong YanjuanYang FanXiao JianyuZhang RuiLiu PengpengCheng YananCao FuliangGuo FengLiu GuoyanMeng BinZhou DejunSun YanRen XiubaoYu JunHao JihuiJiang Hongjing - It has been found that progression from leukoplakia to head and neck squamous cell carcinoma (HNSCC) is a long-term process that may involve changes in the multicellular ecosystem. We acquired scRNA-seq samples information from gene expression omnibus and UCSC Xena database. The BEAM function was used to construct the pseudotime trajectory and analyze the differentially expressed genes in different branches. We used the ssGSEA method to explore the correlation between each cell subgroup and survival time, and obtained the cell subgroup related to prognosis. During the progression from leukoplakia to HNSCC, we found several prognostic cell subgroups, such as AURKB + epithelial cells, SFRP1 + fibroblasts, SLC7A8 + macrophages, FCER1A + CD1C + dendritic cells, and TRGC2 + NK/T cells. All cell subgroups had two different fates, one tending to cell proliferation, migration, and enhancement of angiogenesis capacity, and the other tending to inflammatory immune response, leukocyte chemotaxis, and T cell activation. Tumor-promoting genes such as CD163 and CD209 were highly expressed in the myeloid cells, and depletion marker genes such as TIGIT, LAG3 were highly expressed in NK/T cells. Our study may provide a reference for the molecular mechanism of HNSCC and theoretical basis for the development of new therapeutic strategies. - Source: PubMed
Publication date: 2024/04/06
Wang HaibinGuan ZhenjieZheng Lian - Melanoma is one of the most sensitive tumors to immune modulation, and the major challenge for melanoma patients' survival is immune checkpoint inhibitor (ICI) therapy. γδ T lymphocytes play an antitumoral role in a broad variety of tumors including melanoma and they are optimal candidates for cellular immunotherapy. Thus, a comprehensive analysis of the correlation between γδ T cells and immune checkpoint receptors in the context of melanoma was conducted, with the aim of devising an innovative combined immunotherapeutic strategy. In this study, using the GEPIA2.0 database, a significant positive correlation was observed between the expression of γδ T cell-related genes (TRGC1, TRGC2, TCRD) and immune checkpoint genes (PDCD1, HAVCR2, LAG3), highlighting the potential role of γδ T cells in the immune response within melanoma. Moreover, flow cytometry analysis unveiled a significant augmentation in the population of γδ T cells within melanoma lesions, which exhibited the expression of immune checkpoint receptors including LAG3, TIM3, and PD1. Analysis of single-cell RNA sequencing data revealed a significant enrichment and functional reprogramming of γδ T cell clusters in response to ICIs. Interestingly, the effects of ICI therapy varied between Vδ1 and Vδ2 γδ T cell subsets, with distinct changes in gene expression patterns. Last, a correlation analysis between γδ T cell abundance, immune checkpoint gene expression, and clinical outcomes in melanoma patients showed that low expression of immune checkpoint genes, including LAG3, HAVCR2, and PDCD1, was associated with improved 1-year overall survival, emphasizing the significance of these genes in predicting patient outcomes, potentially outweighing the impact of γδ T cell abundance. This study offers critical insights into the dynamic interaction between γδ T cells, immune checkpoint receptors, and melanoma, providing valuable perspectives for potential therapeutic avenues and predictive markers in this intricate interplay. - Source: PubMed
Di Simone MartaCorsale Anna MariaToia FrancescaShekarkar Azgomi MojtabaDi Stefano Anna BarbaraLo Presti ElenaCordova AdrianaMontesano LuigiDieli FrancescoMeraviglia Serena - Immune checkpoint inhibitors (ICI) have become the standard of care for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer. However, biomarkers of response to ICI are still lacking. - Source: PubMed
Li JianxiaHu HuabinQin GeBai FanWu XianruiKe HaoxianZhang JianweiXie YuqianWu ZehuaFu YangZheng HongboGong LonglongXie ZhiDeng Yanhong - There is an imperative choice to develop a secure feasible strategy to address evasion dynamics of refractory tumors and SARS-CoV-2-variants, while stem cell-based protocol may be more reliable as its unique ability for resetting multifunctional immunity to address progressive tumor and the constantly-evolving virus. In this study, spheroid-embryonoid stem cells from mature somatic cells were engineered as multifunctional biologics (3D-E/BSC) and inoculated in senile rhesus to identify secure potential against immune-evasion from viral-variants. Meanwhile, a cohort of eligible patients with stage IV NSCLC were approved for phase I clinical trials. Subsequently, long-lasting security and efficacy were validated by primate and clinical trials ( < 0.01) in that it could not only stimulate serological immunity, but also reset core immunity for hosts to address variant evasion after 3D-E/BSC withdrawal. Particularly, illustrated by single-cell evolving trajectory, 3D-E/BSC had securely reset senile thymus of aging hosts to remodel core immunity by rearranging naive rhythm to evolve TRGC2/JCHAINNKT clusters to abolish tumoral and viral evasion dynamics with path-feedbacks of NSCLC and COVID-19 simultaneously activated, leading to continuous blockade of breakthrough infection of viral-mutants and long-term survival in one-third of terminal patients without adjuvant required. Our study may pioneer a practical multifunctional strategy to eliminate evasion of SARS-CoV-2 variants and refractory NSCLC so as for victims to restart a new life-equation. - Source: PubMed
Publication date: 2023/06/24
Zhang YannaLi QianLiu NanxiHu JianchuanLin XiaojuanHuang MeijuanWei YuquanQi XiaorongChen Xiancheng